Eagle Pharmaceuticals (EGRX) Reports In-Line Q4 EPS

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q4 EPS of $1.00, in-line with the analyst estimate of $1.00. Revenue for the quarter came in at $46.8 million versus the consensus estimate of $52.91 million.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.

You May Also Be Interested In

• Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations
• Methanex to idle Trinidad Titan plant after gas contract talks fail
• Hormel Foods agrees to sell Brazil's Ceratti brand to Zanchetta